CLL
News
Safer CAR uses modified NK cells for advanced CLL, NHL
News
Novel mutations contribute to progression of venetoclax-treated CLL
In comparison to wild-type aspartic acid, the BCL2 Asp103Glu substitution was linked to an approximate 20-fold reduction in affinity for...
News
Ofatumumab works safely for elderly patients with CLL, comorbidities
The overall response rate to the anti-CD20 antibody was 72%, of which 53% were partial and 19% were complete.
News
CAR T-cell therapy may worsen mental health in some patients
News
9/11 responders show increased risk of leukemia, other cancers
This is the first study to show that 9/11 responders have a higher incidence of leukemia than the general population.
Conference Coverage
CAR T-cell therapy advances in CLL
ORLANDO – The safety and clinical activity of the CD19-directed CAR T-cell agent justifies moving forward with phase 2 investigation, researchers...
Conference Coverage
LOXO-305: Next-gen BTK inhibitor safe and effective in B-cell malignancies
ORLANDO – The antitumor activity of the novel drug was significant among patients with chronic lymphocytic leukemia and mantle cell lymphoma.
Conference Coverage
Zanubrutinib achieved high response rate in del(17p) CLL cohort
ORLANDO – The study looked at responses in a cohort of patients with historically poor prognosis and response to chemotherapy.
Conference Coverage
Efficacy of postvenetoclax therapy may depend on prior agent exposure in CLL
ORLANDO – The multicenter study was aimed at addressing the knowledge gap around what therapy to use after venetoclax.
Conference Coverage
Off-the-shelf cellular therapy shows promise in the lab
ORLANDO – Findings from this preclinical research support moving forward with a phase 1 study of the therapy, as monotherapy or combined with...